Objective: The aim of our study was to explore the inhibitory effect of Tagalsin on murine transplanted tumour and its anti-tumour mechanisms. Methods: Animal models were established by transplanting H22 hepatoma cells to the left oxter of mice, and ten days later they were randomly divided into five groups: blank control group (edible oil), positive control group (HCFU) and Tagalsin group, including low-dose, middle-dose and high-dose group. All mice were killed 24 h after medication, during which observation was conducted concerning survival conditions, body weight changes, spleen weight and tumor weight of tumor-bearing mice; the spleen index and the tumor inhibitor rate (IR) were calculated and pathological changes of tumor-bearing mice were observed by HE dye. Apoptosis factors p53 and Survivin mRNA were detected by reverse transcription polymerase chain reaction (RT-PCR). Results: Tagalsin can inhibit hepatoma growth effectively without influencing spleen index and body weight, the tumor inhibitor rate (IR) of low, middle and high dose group of Tagalsin were 15.81%, 36.75% and 74.79% respectively, the tumor inhibitor rate (IR) of HCFU were 73.93%. Apoptosis cells could be found from the specimen of the positive control group and Tagalsin groups. Reverse transcription polymerase chain reaction (RT-PCR) results showed that positive control group’s and Tagalsin treatment groups’ p53 gene expression enhanced significantly and Survivin gene expression dropped comparing with blank group (P < 0.05). Conclusion: Tagalsin can inhibit growth of the H22 hepatoma cells significantly, the mechanism of anti-tumor effect may work by up-regulating p53 expression and down-regulating Survivin expression. Tagalsin may be considered as a potential candidate for chemoprevention. Objective: The aim of our study was to explore the inhibitory effect of Tagalsin on murine transplanted tumour and its anti-tumour mechanisms. Methods: Animal models were established by transplanting H22 hepatoma cells to the left oxter of mice, and ten days later All mice were killed 24 h after medication, HCFU and Tagalsin group, including low-dose, middle-dose and high-dose group. Was conducted concerning survival conditions, body weight changes, spleen weight and tumor weight of tumor-bearing mice; the spleen index and the tumor inhibitor rate (IR) were calculated and pathological changes of tumor-bearing mice were observed by HE dye. Apoptosis factors Results: Tagalsin can inhibit hepatoma growth effectively without influencing spleen index and body weight, t The hepatic inhibitor inhibitor rate (IR) of low, middle and high dose group of Tagalsin were 15.81%, 36.75% and 74.79% respectively, the tumor inhibitor rate (IR) of HCFU were 73.93%. Apoptosis cells could be found from the specimen of The positive control group and Tagalsin groups. Reverse transcription polymerase chain reaction (RT-PCR) results showing that positive control group’s and Tagalsin treatment groups’ p53 gene expression enhanced significantly and Survivin gene expression dropped comparing with blank group (P < 0.05). : Tagalsin can inhibit growth of the H22 hepatoma cells significantly, the mechanism of anti-tumor effect may work by up-regulating p53 expression and down-regulating Survivin expression. Tagalsin may be considered as a potential candidate for chemoprevention.